Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.58 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.58 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.58 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.58 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.55 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.55 |
| ▸ | DTYMK | P23919 | 2/20 | 0.54 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29664985 | 1.00 | POLB (0.61) | POLBP2RY1P2RY2P2RX3P2RX2 | |
| SCHEMBL1064092 | 1.00 | POLB (0.61) | POLBP2RY1P2RY2P2RX3P2RX2 | |
| SCHEMBL15721195 | 1.00 | POLB (0.61) | POLBP2RY1P2RY2P2RX3P2RX2 | |
| SCHEMBL26779529 | 0.92 | P2RX3 (0.64) | POLBP2RY1P2RY2P2RX3P2RX2 | |
| SCHEMBL30381713 | 0.92 | POLB (0.62) | POLBP2RY1P2RY2P2RX3P2RX2 | |
| SCHEMBL31685679 | 0.92 | ADORA3 (0.62) | POLBP2RY1ENPP1ADORA3 | |
| SCHEMBL16203365 | 0.88 | POLB (0.64) | POLBP2RY1P2RY2P2RX3P2RX2 | |
| SCHEMBL29465233 | 0.87 | POLB (0.65) | POLBP2RY1P2RY2P2RX3P2RX2 | |
| SCHEMBL245486 | 0.87 | POLB (0.65) | POLBP2RY1P2RY2P2RX3P2RX2 | |
| SCHEMBL1763078 | 0.87 | POLB (0.65) | POLBP2RY1P2RY2P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034677-B2 | Coumarin-based compounds and related methods | BIOSEARCH TECHNOLOGIES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20170015652-A1 | Coumarin-based compounds and related methods | BIOSEARCH TECHNOLOGIES, INC. | 2017-01-19 | — | — | US | disclosed |
| US-8524898-B2 | Proton acceptor iminium/carbocation-type coupling agents | LUXEMBOURG BIO TECHNOLOGIES LTD. (IL) | 2013-09-03 | — | — | US | disclosed |
| US-20100144588-A1 | PROTON ACCEPTOR IMINIUM/CARBOCATION-TYPE COUPLING AGENTS | LUXEMBOURG BIO TECHNOLOGIES LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| EP-2170822-A2 | PROTON ACCEPTOR IMINIUM/CARBOCATION-TYPE COUPLING AGENTS | Luxembourg Bio Technologies Ltd. (IL) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008139481-A2 | PROTON ACCEPTOR IMINIUM/CARBOCATION-TYPE COUPLING AGENTS | LUXEMBOURG BIO TECHNOLOGIES LTD. (IL) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034677-B2 | Coumarin-based compounds and related methods | HCCS, FBL, COIL | POLB 119/4885P2RY1 4441/4885P2RY2 4580/4885 |
| US-20170015652-A1 | Coumarin-based compounds and related methods | HCCS, FBL, COIL | POLB 119/4885P2RY1 4441/4885P2RY2 4580/4885 |
| US-20100144588-A1 | PROTON ACCEPTOR IMINIUM/CARBOCATION-TYPE COUPLING AGENTS | PHAX, GIPR, IAPP | POLB 156/4885P2RY1 407/4885P2RY2 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.